#3 - CRISPR Therapeutics (NASDAQ:CRSP)
The biotech sector is notoriously volatile. In the last 18 months when Covid-19 vaccines and therapeutics have boosted the valuations of many companies in the sector. However, that will turn investors' attention to the field of gene editing. And that’s why you should consider CRISPR Therapeutics (NASDAQ:CRSP).
The company has a partnership with Vertex Pharmaceuticals (NASDAQ:VRTX) to bring its lead gene therapy candidate out of clinical trials. CTX001 is a potentially curative gene therapy for both sickle cell disease and transfusion-dependent beta-thalassemia.
The words “revolutionary” and “game-changer” can be overused. Gene editing is an exciting field that is worthy of both of those terms. Nevertheless, there’s no assurance that the company will get one, or multiple, products through clinical trials. And in an environment where investors are fleeing from risk, CRSP stock can look risky.
But if you have a stomach for the speculation, analysts give the stock a $152.33 price target which is a 159% upside.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More - Current Price
- $40.72
- Consensus Rating
- Hold
- Ratings Breakdown
- 9 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $77.93 (91.4% Upside)
